{"id":"W4322422773","doi":"10.1016/s1470-2045(23)00049-9","title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study","year":2023,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; University of Alberta","funders":"","keywords":"Lenvatinib; Medicine; Sunitinib; Renal cell carcinoma; Pembrolizumab; Everolimus; Internal medicine; Oncology; Clinical endpoint; Kidney cancer; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002520849,0.001625459,0.004031423,0.0004405853,0.0004580906,0.001633962,0.0009897999,0.001883544,0.00487904],"category_scores_gemma":[0.002224938,0.0007267814,0.004014251,0.000520291,0.0009822545,0.002081572,0.0005256936,0.004643684,0.0008896523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001441565,"about_ca_system_score_gemma":0.001188906,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001817581,"about_ca_topic_score_gemma":0.005215129,"domain_scores_codex":[0.9989591,0.0005893877,0.00005306797,0.000144092,0.00007256174,0.0001818243],"domain_scores_gemma":[0.9984757,0.0004869565,0.0003553834,0.000118784,0.00007234123,0.0004907409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9795917,0.002108353,0.0006777376,0.0004554209,0.001641105,0.00003121672,0.00004729745,0.000486708,0.001086548,0.0000514821,0.0006686269,0.01315387],"study_design_scores_gemma":[0.9209279,0.06889055,0.006686389,0.00006901239,0.001413813,0.00006194963,0.00004550071,0.0005908015,0.0002809594,0.0002305583,0.0007740618,0.00002855301],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853932,0.008845246,0.0004044926,0.0008029895,0.0006025457,0.0008593771,0.001192953,0.00008908025,0.001810169],"genre_scores_gemma":[0.9911725,0.002768632,0.0006381772,0.001027228,0.0003489306,0.0007250665,0.001214063,0.00002371411,0.002081722],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00487904,"threshold_uncertainty_score":0.01632196,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1180846668618132,"score_gpt":0.3742417348262079,"score_spread":0.2561570679643946,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}